Tag:
Alkermes
Latest Headlines
Latest Headlines
Amylin's OH plant prepped for Bydureon's U.S. debut
In anticipation of the U.S. approval of Bydureon, San Diego's Amylin Pharmaceuticals ( $AMLN ) was already amping up production of the diabetes drug at its West Chester Township, OH, plant where...
Amylin gets FDA OK for weekly diabetes drug Bydureon
Say hello to Bydureon , a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ( $AMLN ) developed the drug using controlled release drug
UPDATED: FDA (finally) stamps an approval on Amylin's Bydureon
After being rejected twice by regulatory officials, Amylin has finally won FDA approval to sell Bydureon, its once-weekly diabetes jab. The news sent Amylin's shares up 16% while Alkermes ($ALKS),
Civitas gains Michael J. Fox Foundation funding for inhaled Parkinson's treatment trials
Civitas Therapeutics has secured new funding from The Michael J. Fox Foundation for Parkinson's Research, which will support clinical testing of its inhaled Parkinson's therapy through the...
FDA accepts Otsuka's app for long-lasting Abilify
Otsuka Pharmaceutical has taken an important step forward in the development of a once-monthly version of its blockbuster schizophrenia drug Abilify (aripiprazole). U.S. regulators have accepted for...
Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup
Alkermes ( $ALKS ) has come through the divorce between its partners Amylin ( $AMLN ) and Eli Lilly ( $LLY ) unscathed, with all of its royalty rights to sales of extended-release exenatide or Bydureon ,...
After restructuring, Elan focuses on its R&D priorities
For years Elan has struggled to deliver for its investors--with little success. It spent quite some time talking about restructuring without actually accomplishing much. It had to deal with a severe
Alkermes wraps buyout of Elan drug-delivery biz
Alkermes ($ALKS) has jumped into the European biotech scene in style. The provider of drug-delivery technologies has completed its buyout of Elan's drug-delivery business, made Ireland its new
Flying high on Elan deal, Alkermes gets to work on Big Pharma project
Alkermes ( $ALKS ) is taking immediate occupancy of an Elan Drug Technologies' Athalone, Ireland, facility following its $1 billion acquisition of the latter's drug technology business. Alkermes
Alkermes stock upgrade validates drug-delivery focus
FierceDrugDelivery does not ordinarily concern itself too much with company stock prices or financials and prefers, instead, to focus on pure drug-delivery technology wherever it is found. But it
